Pancreatic Cancer

PDAC AT ASCO 2026

Browse all PDAC AT ASCO 2026

PDAC AT ASCO 2026

Clinical Insights: Impact of RASolute 302 on Clinical Practice in Previously Treated Metastatic PDAC

Andrew H. Ko, MD, Shubham Pant, MD, MBBS, Eileen O'Reilly, MD, Rachna Shroff, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

PANCREATIC CANCER: METASTATIC TREATMENT STRATEGIES

Browse all PANCREATIC CANCER: METASTATIC TREATMENT STRATEGIES

PANCREATIC CANCER: METASTATIC TREATMENT STRATEGIES

Choosing Frontline Therapy for Patients With Metastatic Pancreatic Adenocarcinoma

Midhun Malla, MD, Michael A. Morse, MD, FACP, MHS, Benjamin Leon Musher, MD, Janie Y. Zhang, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

PANCREATIC CANCER: METASTATIC TREATMENT STRATEGIES

Frontline Treatment Selection in Metastatic Pancreatic Cancer

Midhun Malla, MD, Michael A. Morse, MD, FACP, MHS, Benjamin Leon Musher, MD, Janie Y. Zhang, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

PANCREATIC CANCER: METASTATIC TREATMENT STRATEGIES

Clinical Insights: Evolving Paradigms in Metastatic Pancreatic Cancer

Midhun Malla, MD, Michael A. Morse, MD, FACP, MHS, Benjamin Leon Musher, MD, Janie Y. Zhang, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD